Skip to main content

 9X26 | pdb_00009x26

Crystal structure of CDK12/Cyclin K in complex with covalent inhibitor ZLC853


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.28 Å
  • R-Value Free: 
    0.247 (Depositor), 0.246 (DCC) 
  • R-Value Work: 
    0.197 (Depositor), 0.199 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9X26

Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history. 

Literature

Discovery and preclinical evaluation of ZLC853 as a potential clinical candidate covalently targeting CDK12/13 kinases.

Zhou, K., Zhou, L., Tien, J.C., Huang, W., Liu, W., Sun, X., Fan, B., Huang, X., Wang, J., Chang, Y., Yang, J., Yin, Y., Su, C., Li, Q., Mannan, R., Mahapatra, S., Cheng, Y., Todd, A.J., Wheeler, C.E., Li, S., Zhou, Y., Ren, X., Wang, G.X., Wang, Z., Chinnaiyan, A.M., Ding, K.

(2026) Acta Pharm Sin B 16: 7554-7572

  • DOI: https://doi.org/10.1016/j.apsb.2026.07.041
  • Primary Citation Related Structures: 
    9X26

  • PubMed Abstract: 

    Previous studies highlight the therapeutic promise of inhibiting cyclin-dependent kinases 12 and 13 (CDK12/13) for castration-resistant prostate cancer (CRPC) and other malignancies. However, developing small molecule modulators of CDK12/13 that exhibit an optimal combination of potency, selectivity and favorable pharmacokinetics (PK) remains challenging. In this study, we present ZLC853 , a potent, selective, and orally bioavailable covalent inhibitor of CDK12/13 developed through PK-oriented optimization of our previously reported inhibitor YJZ5118. ZLC853 potently inhibited CDK12 and CDK13 with IC 50 values of 40.0 and 18.2 nmol/L, respectively, and displayed exceptional kinase selectivity in a comprehensive KinomeScan assay. Its covalent binding mechanism was unequivocally validated through mass spectrometry, co-crystal structure analysis, cellular pull-down assays, and washout experiments. Functionally, ZLC853 suppressed the transcription of DNA damage response genes, induced DNA damage, and promoted apoptosis. Additionally, ZLC853 exhibited good oral bioavailability and robust antitumor activity across multiple prostate cancer models, both in vitro and in vivo , supporting it as a promising candidate for clinical investigation.


  • Organizational Affiliation: 
    • State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.

Macromolecule Content 

  • Total Structure Weight: 67.12 kDa 
  • Atom Count: 4,478 
  • Modeled Residue Count: 561 
  • Deposited Residue Count: 568 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Cyclin-dependent kinase 12324Homo sapiensMutation(s): 0 
Gene Names: CDK12, CRK7, CRKRS, KIAA0904
EC: 2.7.11.22 (PDB Primary Data), 2.7.11.23 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for Q9NYV4 (Homo sapiens)
Explore Q9NYV4 
Go to UniProtKB:  Q9NYV4
PHAROS:  Q9NYV4
GTEx:  ENSG00000167258 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9NYV4
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
Cyclin-KB [auth C]244Homo sapiensMutation(s): 0 
Gene Names: CCNK, CPR4
UniProt & NIH Common Fund Data Resources
Find proteins for O75909 (Homo sapiens)
Explore O75909 
Go to UniProtKB:  O75909
PHAROS:  O75909
GTEx:  ENSG00000090061 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO75909
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A1EYW
(Subject of Investigation/LOI)

Query on A1EYW



Download:Ideal Coordinates CCD File
C [auth A](2S)-N-[2-[4-(dimethylamino)piperidin-1-yl]-5-[[(1S)-1-(4-fluorophenyl)ethyl]carbamoyl-[4-(quinazolin-2-ylamino)cyclohexyl]amino]pyridin-3-yl]-2-fluoranyl-propanamide
C38 H47 F2 N9 O2
PARIKSVHQJWZDT-GQUBXBKDSA-N
Modified Residues  1 Unique
IDChains Modified ResidueModification TypeFormula2D Diagram
TPO
Query on TPO
THRPhosphorylationC4 H10 N O6 P

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.28 Å
  • R-Value Free:  0.247 (Depositor), 0.246 (DCC) 
  • R-Value Work:  0.197 (Depositor), 0.199 (DCC) 
Space Group: P 31 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 114.12α = 90
b = 114.12β = 90
c = 103.06γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
Aimlessdata scaling
XDSdata reduction
gemmidata extraction
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Science Foundation (NSF, China)China22577147

Revision History  (Full details and data files)

  • Version 1.0: 2026-10-07
    Type: Initial release
  • Version 1.1: 2026-11-18
    Changes: Database references